

Global Clinical Biomarkers Market: Focus on Product, Technology, End User, Clinical Area, Region, and Competitive Landscape – Analysis and Forecast, 2019-2029

<https://marketpublishers.com/r/G8D84A6B83BAEN.html>

Date: March 2020

Pages: 213

Price: US\$ 5,000.00 (Single User License)

ID: G8D84A6B83BAEN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the global clinical biomarkers market?

What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?

What are the key technologies that have been used by leading players in the market for the development of biomarkers-based assays?

How each segment of the market is expected to grow during the forecast period from 2019 to 2029 based on:

Product type

Clinical area

Technology

End user

Region: Region includes North America, Europe, Asia-Pacific, Rest-of-the-World (ROW)

Who are the leading players with significant offerings to the global clinical biomarkers market? What is the expected market dominance for each of these leading players?

Which companies are anticipated to be highly disruptive in the future and why?

Global Clinical Biomarkers Market, 2019-2029

Global clinical biomarkers market analysis by BIS Research projects the market to grow at a significant CAGR of 10.07% during the forecast period, 2019-2029. Global clinical biomarkers market generated \$16.01 billion revenue in 2018, in terms of value.

The growth in global clinical biomarkers market is anticipated to be driven by increasing prevalence of infectious diseases, increase in adoption of personalized medicine, growing focus on biomarker research and development programs and rising demand for non-invasive diagnosis. However, there are potential restraining factors hindering the growth of the market. These factors include uncertain reimbursement policies pertaining to clinical biomarkers-based products, requirement of high capital investment, and issues related to clinical validity of biomarkers.

Expert Quote

“Efficient translation of MS-based biomarker discovery research into the development of routine clinical diagnostic assays is an important challenge in the field of personalized medicine.”

Scope of the Market Intelligence on Global Clinical Biomarkers Market

Global clinical biomarkers market research provides a holistic view of the market in terms of various factors influencing it, including strategic developments and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the industrial and biological research. In addition, the

study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global clinical biomarkers market.

Market Segmentation

Global clinical biomarkers market (on the basis of type) is segmented into diagnostic, prognostic and predictive biomarkers.

Global clinical biomarkers market (on the basis of clinical area) is segmented into cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease, immunological biomarkers, non-invasive prenatal testing and other clinical areas.

Global clinical biomarkers market (on the basis of technology) is segmented into real-time polymerase chain reaction, next-generation sequencing, Enzyme-linked immunosorbent assay (ELISA), and other technologies.

Global clinical biomarkers market (on the basis of end user) is segmented into research and academic laboratories, diagnostic centers, biopharmaceutical and biotech companies and other end users.

Key companies in the Global Clinical Biomarkers Market

The report also comprises 15 detailed company profiles including several key players, such as Abbott Laboratories, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Myriad Genetics, Hologic, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Enzo Biochem Inc., Centogene N.V., ALCEDIAG, and Quest Diagnostics Incorporated.

Contents

EXECUTIVE SUMMARY

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 MARKET SCOPE

2.1 Scope of Work

2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 Global Clinical Biomarkers Market: Research Methodology

3.2 Data Sources

3.3 Secondary Data Sources

3.4 Market Estimation Model

3.5 Criteria for Company Profiling

4 MARKET OVERVIEW

4.1 Introduction

4.2 Clinical Biomarkers Approaches in Precision Medicine

4.3 Market Available Clinical Biomarkers

4.4 Global Footprint

5 GLOBAL CLINICAL BIOMARKERS MARKET: MARKET DYNAMICS

5.1 Overview

5.2 Impact Analysis

5.3 Market Drivers

5.3.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally

5.3.2 Increase in Adoption of Personalized Medicine

5.3.3 Growing Focus on Biomarkers Research and Development Programs

5.3.4 Rising Demand for Non-Invasive Diagnosis

5.4 Market Restraints

- 5.4.1 Uncertain Reimbursement Policies Pertaining to Clinical Biomarkers
- 5.4.2 Requirement of High Capital Investment Hindering Expansion
- 5.4.3 Issues Related to Clinical Validity of Biomarkers-Based Tests
- 5.5 Market Opportunities
 - 5.5.1 Massive Scope for Adoption of Clinical Biomarkers in Emerging Nations
 - 5.5.2 Technological Advancements in Clinical Biomarkers-Based Tests
 - 5.5.3 Increased Use of Clinical Biomarkers in Widespread Applications

6 COMPETITIVE LANDSCAPE

- 6.1 Key Strategies and Developments
 - 6.1.1 Synergistic Activities
 - 6.1.2 Product Approvals
 - 6.1.3 Product Launches and Upgradations
 - 6.1.4 Mergers and Acquisitions
 - 6.1.5 Funding and Expansion
- 6.2 Market Share Analysis
- 6.3 Growth Share Analysis (Opportunity Mapping)
 - 6.3.1 By Company

7 GLOBAL CLINICAL BIOMARKERS MARKET (BY TYPE), 2018-2029

- 7.1 Diagnostic Biomarkers
- 7.2 Predictive Biomarkers
- 7.3 Prognostic Biomarkers

8 GLOBAL CLINICAL BIOMARKERS MARKET (BY CLINICAL AREA), 2018-2029

- 8.1 Cancer Biomarkers
 - 8.1.1 Breast Cancer Biomarkers
 - 8.1.2 Lung Cancer Biomarkers
 - 8.1.3 Colorectal Cancer Biomarkers
 - 8.1.4 Prostate Cancer Biomarkers
- 8.2 Cardiac Biomarkers
- 8.3 Neurological Biomarkers
- 8.4 Infectious Disease
- 8.5 Immunological Biomarkers
- 8.6 Non-Invasive Prenatal Testing
- 8.7 Other Clinical Areas

9 GLOBAL CLINICAL BIOMARKERS MARKET (BY TECHNOLOGY), 2018-2029

- 9.1 Real-Time PCR
- 9.2 Enzyme-Linked Immuno Sorbent Assay (ELISA)
- 9.3 Immunohistochemistry (IHC)
- 9.4 Next-Generation Sequencing (NGS)
- 9.5 Other Technologies

10 GLOBAL CLINICAL BIOMARKERS MARKET (BY END USER), 2018-2029

- 10.1 Overview
- 10.2 Research and Academic Laboratories
- 10.3 Biopharmaceutical and Biotech Companies
- 10.4 Diagnostic Centers
- 10.5 Other End Users

11 GLOBAL CLINICAL BIOMARKERS MARKET (BY REGION), 2018-2029

- 11.1 Overview
- 11.2 North America
 - 11.2.1 U.S.
 - 11.2.2 Canada
- 11.3 Europe
 - 11.3.1 Germany
 - 11.3.2 U.K.
 - 11.3.3 France
 - 11.3.4 Italy
 - 11.3.5 Spain
 - 11.3.6 Rest-of-Europe
- 11.4 Asia-Pacific
 - 11.4.1 China
 - 11.4.2 Japan
 - 11.4.3 India
 - 11.4.4 Australia
 - 11.4.5 Singapore
 - 11.4.6 Rest-of-APAC
- 11.5 Latin America
 - 11.5.1 Brazil

- 11.5.2 Mexico
- 11.5.3 Rest-of-Latin America
- 11.6 Rest-of-the-World

12 COMPANY PROFILES

- 12.1 Overview
- 12.2 Abbott Laboratories
 - 12.2.1 Company Overview
 - 12.2.2 Role of Abbott Laboratories plc in the Global Clinical Biomarkers Market
 - 12.2.3 Financials
 - 12.2.4 Key Insights about Financial Health of the Company
 - 12.2.5 SWOT Analysis
- 12.3 Agilent Technologies, Inc.
 - 12.3.1 Company Overview
 - 12.3.2 Role of Agilent Technologies, Inc. in the Global Clinical Biomarkers Market
 - 12.3.3 Financials
 - 12.3.4 Key Insights about Financial Health of the Company
 - 12.3.5 SWOT Analysis
- 12.4 ALCEDIAG
 - 12.4.1 Company Overview
 - 12.4.2 Role of ALCEDIAG in Global Clinical Biomarkers Market
 - 12.4.3 SWOT Analysis
- 12.5 Becton, Dickinson and Company
 - 12.5.1 Company Overview
 - 12.5.2 Role of Becton, Dickinson and Company in the Global Clinical Biomarkers Market
 - 12.5.3 Financials
 - 12.5.4 Key Insights about Financial Health of the Company
 - 12.5.5 SWOT Analysis
- 12.6 bioMérieux S.A.
 - 12.6.1 Company Overview
 - 12.6.2 Role of bioMérieux S.A. in the Global Clinical Biomarkers Market
 - 12.6.3 Financials
 - 12.6.4 Key Insights about Financial Health of the Company
 - 12.6.5 SWOT Analysis
- 12.7 Bio-Rad Laboratories, Inc.
 - 12.7.1 Company Overview
 - 12.7.2 Role of Bio-Rad Laboratories, Inc. in the Global Clinical Biomarkers Market

- 12.7.3 Financials
- 12.7.4 Key Insights about Financial Health of the Company
- 12.7.5 SWOT Analysis
- 12.8 CENTOGENE N.V.
 - 12.8.1 Company Overview
 - 12.8.2 Role of CENTOGENE N.V. in the Global Clinical Biomarkers Market
 - 12.8.3 Financials
 - 12.8.4 Key Insights about Financial Health of the Company
 - 12.8.5 SWOT Analysis
- 12.9 F. Hoffmann-La Roche Ltd.
 - 12.9.1 Company Overview
 - 12.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Clinical Biomarkers Market
 - 12.9.3 Financials
 - 12.9.4 Key Insights about Financial Health of the Company
 - 12.9.5 SWOT Analysis
- 12.10 Enzo Biochem Inc.
 - 12.10.1 Company Overview
 - 12.10.2 Role of Enzo Biochem Inc. in the Global Clinical Biomarkers Market
 - 12.10.3 Financials
 - 12.10.4 Key Insights about Financial Health of the Company
 - 12.10.5 SWOT Analysis
- 12.11 Hologic, Inc.
 - 12.11.1 Company Overview
 - 12.11.2 Role of Hologic, Inc. in the Global Clinical Biomarkers Market
 - 12.11.3 Financials
 - 12.11.4 Key Insights about Financial Health of the Company
 - 12.11.5 SWOT Analysis
- 12.12 Illumina, Inc.
 - 12.12.1 Company Overview
 - 12.12.2 Role of Illumina, Inc. in the Global Clinical Biomarkers Market
 - 12.12.3 Financials
 - 12.12.4 Key Insights about Financial Health of the Company
 - 12.12.5 SWOT Analysis
- 12.13 Myriad Genetics, Inc.
 - 12.13.1 Company Overview
 - 12.13.2 Role of Myriad Genetics, Inc. in the Global Clinical Biomarkers Market
 - 12.13.3 Financials
 - 12.13.4 Key Insights about Financial Health of the Company
 - 12.13.5 SWOT Analysis

12.14 Quest Diagnostics Incorporated

12.14.1 Company Overview

12.14.2 Role of Quest Diagnostics Incorporated in the Global Clinical Biomarkers

Market

12.14.3 Financials

12.14.4 SWOT Analysis

12.15 QIAGEN N.V.

12.15.1 Company Overview

12.15.2 Role of QIAGEN N.V. plc in the Global Clinical Biomarkers Market

12.15.3 Financials

12.15.4 Key Insights about Financial Health of the Company

12.15.5 SWOT Analysis

12.16 Thermo Fisher Scientific Inc.

12.16.1 Company Overview

12.16.2 Role of Thermo Fisher Scientific in the Global Clinical Biomarkers Market

12.16.3 Financials

12.16.4 Key Insights about Financial Health of the Company

12.16.5 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 4.1: Key Commercialized Products Offered by Major Market Players

Table 5.1: Impact Analysis of Market Drivers

Table 5.2: Impact Analysis of Market Restraints

Table 8.1: Key Cancer Biomarkers Products Offered by Major Market Players

Table 8.2: Key Cancer Biomarkers Products Offered by Major Market Players

Table 8.3: Key Lung Cancer Biomarkers Products Offered by Major Market Players

Table 8.4: Key Colorectal Cancer Biomarkers Products Offered by Major Market Players

Table 8.5: Key Prostate Cancer Biomarkers Products Offered by Major Market Players

Table 8.6: Key Cardiac Biomarkers Products Offered by Major Market Players

Table 8.7: Key Neurological Biomarkers Products Offered by Major Market Players

Table 8.8: Key Infectious Disease Biomarkers Products Offered by Major Market
Players

Table 8.9: Key Immunological Biomarkers Products Offered by Major Market Players

Table 8.10: Key Immunological Biomarkers Products Offered by Major Market Players

Table 8.11: Key Immunological Biomarkers Products Offered by Major Market Players

Table 9.1: Key RT-PCR-Based Biomarkers Products Offered by Major Market Players

Table 9.2: Key ELISA-Based Biomarkers Products Offered by Major Market Players

Table 9.3: Key IHC-Based Biomarkers Products Offered by Major Market Players

Table 9.4: Key NGS-Based Biomarkers Products Offered by Major Market Players

Table 9.5: Other Technologies-Based Biomarkers Products Offered by Major Market
Players

List Of Figures

LIST OF FIGURES

Figure 1: Total Global Disease Burden by Cause, 2017

Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Clinical Biomarkers Market

Figure 3: Share of Key Developments and Strategies, 2016-2019

Figure 4: Dominating Segments of the Global Clinical Biomarkers Market, 2019 and 2029

Figure 5: Global Clinical Biomarkers Market (by Product), 2019 and 2029

Figure 6: Global Clinical Biomarkers Market (by Clinical Area), 2019 and 2029

Figure 7: Global Clinical Biomarkers Market (by Technology), 2019 and 2029

Figure 8: Global Clinical Biomarkers Market (by End User), 2019 and 2029

Figure 9: Global Clinical Biomarkers Market (by Region), 2019 and 2029

Figure 2.1: Global Clinical Biomarkers Market Segmentation

Figure 3.1: Global Clinical Biomarkers Market Research Methodology

Figure 3.2: Primary Research Methodology

Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)

Figure 3.4: Top-Down Approach (Segment-Wise Analysis)

Figure 4.1: Global Clinical Biomarkers Market, 2018 and 2029 (\$Billion)

Figure 5.1: Number of Deaths by Top 18 Infectious Diseases, 2015

Figure 5.2: Number of Deaths (in Million) by Different Forms of Cancer, 2018

Figure 6.1: Share of Key Developments and Strategies, 2016–2019

Figure 6.2: Synergistic Activities Share (by Company), 2016 – 2019

Figure 6.3: Product Approval Share (by Company), 2016 –2019

Figure 6.4: Product Launches and Upgrades Share (by Company), 2016 –2019

Figure 6.5: Mergers and Acquisitions Share (by Company), 2016 –2019

Figure 6.6: Market Share Analysis for the Global Clinical Biomarkers Market, 2018

Figure 6.7: Growth Share Matrix for Global Clinical Biomarkers Market (by Company), 2018

Figure 7.1: Global Clinical Biomarkers Market (by Type), 2018-2029 (\$Billion)

Figure 7.2: Global Clinical Biomarkers Market for Diagnostic Biomarkers, 2018-2029 (\$Billion)

Figure 7.3: Global Clinical Biomarkers Market for Predictive Biomarkers, 2018-2029 (\$Billion)

Figure 7.4: Global Clinical Biomarkers for Prognostic Biomarkers, 2018-2029 (\$Billion)

Figure 8.1: Global Clinical Biomarkers Market (by Clinical Area), 2018-2029 (\$Billion)

Figure 8.2: Global Clinical Biomarkers Market for Cancer Biomarkers, 2018-2029

(\$Billion)

Figure 8.3: Global Clinical Biomarkers Market for Breast Cancer Biomarkers, 2018-2029

(\$Billion)

Figure 8.4: Global Clinical Biomarkers Market for Lung Cancer Biomarkers, 2018-2029

(\$Billion)

Figure 8.5: Global Clinical Biomarkers Market for Colorectal Cancer Biomarkers, 2018-2029 (\$Billion)

Figure 8.6: Global Clinical Biomarkers Market for Prostate Cancer Biomarkers, 2018-2029 (\$Billion)

Figure 8.7: Global Clinical Biomarkers Market for Cardiac Biomarkers, 2018-2029 (\$Billion)

Figure 8.8: Global Clinical Biomarkers Market for Neurological Biomarkers, 2018-2029 (\$Billion)

Figure 8.9: Global Clinical Biomarkers Market for Infectious Disease Biomarkers, 2018-2029 (\$Billion)

Figure 8.10: Global Clinical Biomarkers Market for Immunological Biomarkers, 2018-2029 (\$Billion)

Figure 8.11: Global Clinical Biomarkers Market for Non-Invasive Prenatal Testing, 2018-2029 (\$Billion)

Figure 8.12: Global Clinical Biomarkers Market for Other Clinical Areas, 2018-2029 (\$Billion)

Figure 9.1: Global Clinical Biomarkers Market for Real Time PCR, 2018-2029 (\$Billion)

Figure 9.2: Global Clinical Biomarkers Market for ELISA, 2018-2029 (\$Billion)

Figure 9.3: Global Clinical Biomarkers Market for IHC, 2018-2029 (\$Billion)

Figure 9.4: Global Clinical Biomarkers Market for NGS, 2018-2029 (\$Billion)

Figure 9.5: Global Clinical Biomarkers Market for Other Technologies, 2018-2029 (\$Billion)

Figure 10.1: Global Clinical Biomarkers Market (by End User)

Figure 10.2: Global Clinical Biomarkers Market (by End User), 2018-2029 (\$Billion)

Figure 10.3: Global Clinical Biomarkers Market for Research and Academic Laboratories, 2018-2029 (\$Billion)

Figure 10.4: Global Clinical Biomarkers Market for Biopharmaceutical and Biotech Companies, 2018-2029 (\$Billion)

Figure 10.5: Global Clinical Biomarkers Market for Diagnostic Centres, 2018-2029 (\$Billion)

Figure 10.6: Global Clinical Biomarkers Market for Other End Users, 2018-2029 (\$Billion)

Figure 11.1: Global Clinical Biomarkers Market (by Region), 2019 and 2029 (\$Billion)

Figure 11.2: Global Clinical Biomarkers Market (by Region), 2018-2029 (\$Billion)

Figure 11.3: Global Clinical Biomarkers Market Share (by Region), 2018 (\$Billion)

Figure 11.4: Global Clinical Biomarkers Market Share (by Region), 2029 (\$Billion)

Figure 11.5: North America Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.6: North America Clinical Biomarkers Market (by Country), 2018-2029 (\$Billion)

Figure 11.7: North America: Market Dynamics

Figure 11.8: The U.S. Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.9: Canada Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.10: Europe Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.11: Europe: Market Dynamics

Figure 11.12: Europe Clinical Biomarkers Market (by Country), 2018-2029 (\$Billion)

Figure 11.13: Germany Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.14: U.K. Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.15: France Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.16: Italy Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.17: Spain Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.18: Rest-of-Europe Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.19: Asia-Pacific Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.20: APAC: Market Dynamics

Figure 11.21: APAC Global Clinical Biomarkers Market (by Country), 2018-2029 (\$Billion)

Figure 11.22: China Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.23: Japan Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.24: India Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.25: Australia Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.26: Singapore Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.27: Rest-of-Asia Pacific Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.28: Latin America Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.29: Latin America: Market Dynamics

Figure 11.30: Latin America Clinical Biomarkers Market (by Country), 2018-2029 (\$Billion)

Figure 11.31: Brazil Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.32: Mexico Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.33: Rest-of-Latin America Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 11.34: RoW Clinical Biomarkers Market, 2018-2029 (\$Billion)

Figure 12.1: Total Number of Companies Profiled

Figure 12.2: Abbott Laboratories: Overall Product Portfolio

Figure 12.3: Abbott Laboratories: Overall Financials, 2016-2018

Figure 12.4: Abbott Laboratories: Revenue (by Segment), 2016-2018

- Figure 12.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
- Figure 12.6: Abbott Laboratories: Revenue (by Region), 2016-2018
- Figure 12.7: Abbott Laboratories: R&D Expenditure, 2016-2018
- Figure 12.8: Abbott Laboratories: SWOT Analysis
- Figure 12.9: Agilent Technologies, Inc.: Overall Product Portfolio
- Figure 12.10: Agilent Technologies, Inc.: Overall Financials, 2017-2019
- Figure 12.11: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
- Figure 12.12: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
- Figure 12.13: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
- Figure 12.14: Agilent Technologies, Inc.: SWOT Analysis
- Figure 12.15: ALCEDIAG: Overall Product Portfolio
- Figure 12.16: ALCEDIAG: SWOT Analysis
- Figure 12.17: Becton, Dickinson and Company: Overall Product Portfolio
- Figure 12.18: Becton, Dickinson and Company: Overall Financials, 2017-2019
- Figure 12.19: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019
- Figure 12.20: Becton, Dickinson and Company: Revenue (by Sub-Segment – BD Life Sciences), 2017-2019
- Figure 12.21: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
- Figure 12.22: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
- Figure 12.23: Becton, Dickinson and Company: SWOT Analysis
- Figure 12.24: bioMérieux S.A.: Overall Product Portfolio
- Figure 12.25: bioMérieux S.A.: Overall Financials, 2016-2018
- Figure 12.26: bioMérieux S.A.: Revenue (by Segment), 2016-2018
- Figure 12.27: bioMérieux S.A.: Revenue (by Region), 2016-2018
- Figure 12.28: bioMérieux S.A.: R&D Expenditure, 2016-2018
- Figure 12.29: bioMérieux S.A.: SWOT Analysis
- Figure 12.30: Bio-Rad Laboratories, Inc: Overall Product Portfolio
- Figure 12.31: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
- Figure 12.32: Bio-Rad Laboratories, Inc.: Sales (by Segment), 2016-2018
- Figure 12.33: Bio-Rad Laboratories, Inc.: Sales (by Region), 2016-2018
- Figure 12.34: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
- Figure 12.35: Bio-Rad Laboratories, Inc.: SWOT Analysis
- Figure 12.36: CENTOGENE N.V.: Overall Product Portfolio
- Figure 12.37: CENTOGENE N.V.: Overall Financials, 2016-2018
- Figure 12.38: CENTOGENE N.V.: Sales (by Segment), 2016-2018
- Figure 12.39: CENTOGENE N.V.: Sales (by Region), 2016-2018
- Figure 12.40: CENTOGENE N.V.: R&D Expenditure, 2016-2018
- Figure 12.41: CENTOGENE N.V.: SWOT Analysis
- Figure 12.42: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio

- Figure 12.43: F. Hoffmann-La Roche Ltd.: Overall Financials, 2016-2018
- Figure 12.44: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2016-2018
- Figure 12.45: F. Hoffmann-La Roche Ltd.: Sales (by Region), 2016-2018
- Figure 12.46: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2016-2018
- Figure 12.47: F. Hoffmann-La Roche Ltd.: SWOT Analysis
- Figure 12.48: Enzo Biochem Inc.: Overall Product Portfolio
- Figure 12.49: Enzo Biochem Inc.: Overall Financials, 2017-2019
- Figure 12.50: Enzo Biochem Inc.: Revenue (by Segment), 2017-2019
- Figure 12.51: Enzo Biochem Inc.: Revenue (by Region), 2017-2019
- Figure 12.52: Enzo Biochem Inc.: R&D Expenditure, 2017-2019
- Figure 12.53: Enzo Biochem Inc.: SWOT Analysis
- Figure 12.54: Hologic, Inc.: Overall Product Portfolio
- Figure 12.55: Hologic, Inc.: Overall Financials, 2017-2019
- Figure 12.56: Hologic, Inc.: Sales (by Segment), 2017-2019
- Figure 12.57: Hologic, Inc.: Sales (by Region), 2017-2019
- Figure 12.58: Hologic, Inc.: R&D Expenditure, 2017-2019
- Figure 12.59: Hamilton, Inc.: SWOT Analysis
- Figure 12.60: Illumina, Inc.: Overall Product Portfolio
- Figure 12.61: Illumina, Inc.: Overall Financials, 2016-2018
- Figure 12.62: Illumina, Inc.: Sales (by Segment), 2016-2018
- Figure 12.63: Illumina, Inc.: Sales (by Region), 2016-2018
- Figure 12.64: Illumina, Inc.: R&D Expenditure, 2016-2018
- Figure 12.65: Illumina, Inc.: SWOT Analysis
- Figure 12.66: Myriad Genetics, Inc.: Overall Product Portfolio
- Figure 12.67: Myriad Genetics, Inc.: Overall Financials, 2017-2019
- Figure 12.68: Myriad Genetics, Inc.: Sales (by Segment), 2017-2019
- Figure 12.69: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
- Figure 12.70: Myriad Genetics, Inc.: SWOT Analysis
- Figure 12.71: Quest Diagnostics Incorporated, Inc.: Overall Product Portfolio
- Figure 12.72: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
- Figure 12.73: Quest Diagnostics Incorporated.: Sales (by Segment), 2016-2018
- Figure 12.74: Quest Diagnostics Incorporated: SWOT Analysis
- Figure 12.75: QIAGEN N.V.: Overall Product Portfolio
- Figure 12.76: QIAGEN N.V.: Overall Financials, 2016-2018
- Figure 12.77: QIAGEN N.V.: Revenue (by Segment), 2016-2018
- Figure 12.78: QIAGEN N.V.: Revenue (by Region), 2016-2018
- Figure 12.79: QIAGEN N.V.: R&D Expenditure, 2016-2018
- Figure 12.80: QIAGEN N.V.: SWOT Analysis
- Figure 12.81: Thermo Fisher Scientific Inc.: Overall Product Portfolio

Figure 12.82: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018

Figure 12.83: Thermo Fisher Scientific Inc: Sales (by Segment), 2016-2018

Figure 12.84: Thermo Fisher Scientific Inc.: Sales (by Region), 2016-2018

Figure 12.85: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018

Figure 12.86: Thermo Fisher Scientific Inc.: SWOT Analysis

I would like to order

Product name: Global Clinical Biomarkers Market: Focus on Product, Technology, End User, Clinical Area, Region, and Competitive Landscape – Analysis and Forecast, 2019-2029

Product link: <https://marketpublishers.com/r/G8D84A6B83BAEN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8D84A6B83BAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

